Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of G1T48 alone and with palbociclib in ER-positive, HER2-negative advanced breast cancer
NL-OMON50738Phase 1Completed
- Sponsor
- G1 Therapeutics, Inc.
- Start
- Oct 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rintodestrant and palbociclib in breast cancer (3 arms), sponsored by G1 Therapeutics, Inc. Primary endpoints: Adverse events and safety measures and Dose-limiting toxicities, safety and tolerability. Started Oct 2018; status: completed.
02
Drugs
rintodestrantpalbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON50738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50738.